-
Umbilical artery Doppler as a screening test for fetal well-being in a high-risk population was associated with a decreased incidence of cesarean delivery for fetal distress compared to the nonstress testing, with no increase in neonatal morbidity.
-
Twelve cycles of single-agent paclitaxel administered to women with advanced ovarian cancer who attain a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy significantly prolongs the duration of progression-free survival.
-
The WHI and the WELL-HART clinical trials report that hormone therapy does not reduce the risk of coronary events or slow the progression of atherosclerosis in older women.
-
-
The FDA has approved the first once-daily protease inhibitor (PI) for the treatment of HIV-1 infections. Atazanavir (Bristol-Myers Squibb) is the newest PI to enter this relatively crowded class. It is marketed under the trade name Reyataz.
-
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer.
-
The association of caffeine and nicotine in pharmaceutical products and aneurysmal SAH warrants further study.
-
The low-carbohydrate diet produced a greater weight loss than did the conventional diet for the first 6 months, but the differences were not significant at 1 year.
-
Peripheral arterial disease is common. Screening with measurement of the ankle-brachial index will improve detection.
-
Only about 12% of patients with new onset atrial fibrillation who did not have apparent contraindications to warfarin treatment filled prescriptions for it.